Dishman Carbogen Amcis (DCAL) delivered solid Q4FY26 and FY26 results!

Net Revenue jumped 18.9% to ₹851.4 Cr in Q4 and 8.1% to ₹2,931.9 Cr for the full year.

The CDMO segment was a growth engine, up 21.3% in Q4 and 6.5% for FY26, boosted by commercial sales and late Phase III development.

Marketable Molecules also shined, growing 9.3% in Q4 and 17.2% for FY26, driven by higher Vitamin D analogue supplies and better costs.

Full-year EBITDA margin expanded to 19.3%, reflecting improved efficiency.

DCAL's strategy focuses on high-value, complex molecules and leveraging its 10 late-stage Phase III molecules.

The company is actively targeting small/mid-sized global biotech clients and sees oncology as a key growth area.

Recent highlights include renewed GMP certifications for Netherlands and Shanghai facilities, and a reduced net debt of CHF 146.80 mn.

Capex for FY26 was CHF 22.4 mn.